Acrizanib is primarily utilized in the field of medical research and oncology due to its potential as a tyrosine kinase inhibitor. It is being studied for its ability to target and inhibit specific receptors involved in the growth and spread of cancer cells, particularly in cases of advanced or metastatic cancers. Researchers are exploring its efficacy in blocking angiogenesis, the process by which tumors develop new blood vessels to sustain their growth. This makes it a promising candidate for developing targeted cancer therapies, especially in cancers that are resistant to conventional treatments. Additionally, its role in modulating signaling pathways associated with tumor progression is under investigation, offering hope for improved therapeutic outcomes in challenging cancer cases.